A 78-year-old woman presented with fever and a sore throat for five days. Oral Augmentin (amoxicillin/clavulanate potassium) did not reduce the fever. Seven weeks prior to this episode Graves' disease had been diagnosed and treatmnent with methimazole 40 mg once a day and propanolol 10 mg qid was started. On admission, her temperature was 37.6°C, blood pressure was 100/70 mmHg and heart rate 76 beats/min. She had severe aphthous stomatitis with many ulcerations. The thyroid gland was palpable. Physical examination was otherwise unremarkable.
A 78-year-old woman presented with fever and a sore throat for five days. Oral Augmentin (amoxicillin/clavulanate potassium) did not reduce the fever. Seven weeks prior to this episode Graves' disease had been diagnosed and treatmnent with methimazole 40 mg once a day and propanolol 10 mg qid was started. On admission, her temperature was 37.6°C, blood pressure was 100/70 mmHg and heart rate 76 beats/min. She had severe aphthous stomatitis with many ulcerations. The thyroid gland was palpable. Physical examination was otherwise unremarkable. Thyroid-stimulating hormone was 0.8 mU/l (normal 0.3-5.0 mU/l) and free thyroxine was 18.9 nmol/l (normal 9.5-22.4 nmol/l). A blood film (figure) was examined. infection. The use of steroids probably does not alter the recovery time.2 Antithyroid drugs are just some of the many drugs that can cause agranulocytosis. Granulocyte macrophage colony-stimulating factor (GM-CSF) and G-CSF are growth factors which promote the differentiation of the committed progenitor cells into mature macrophages and neutrophils. These colony-stimulating factors act on haematopoietic cells by binding to specific cell surface receptors and stimulating proliferation, differentiation and some end cell functional activation, such as phagocytosis and cytotosis. Endogenous G-CSF is produced when bone marrow granulocyte production is markedly inhibited.
These cytokinins, G-CSF and GM-CSF, have proved useful in the treatment of neutropenia associated with severe aplastic anaemia, myelodysplastic syndrome, in patients receiving myelosuppressive chemotherapy, in patients suffering from AIDS, leukopenia,' and in patients with cyclic neutropenia. 4 Balkin et al5 described a patient with propylthiouracilinduced agranulocytosis, whose bone marrow had a virtual absence of myeloid elements, who responded dramatically to recombinant human G-CSF, while Tamai et al' reported a similar response in patients with methimazole-induced agranulocytosis. Both GM-CSF and G-CSF have been shown to be effective in the treatment of drug-induced agranulocytosis by shortening the recovery period and reducing morbidity and mortality from bacterial and fungal infections. As recombinant human GM-CSF, has dose-limited toxicity and dose limitations have not been shown for recombinant human G-CSF, the latter is recommended for the treatment of agranulocytosis induced by antithyroid drugs. 
